Star fund manager Neil Woodford says £120m punt on US biotech firm could still come good despite estimated £32m loss 

In a letter to investors in his £8bn Equity Income Fund and Patient Capital Trust, Woodford said it was too soon to say whether the £120m bet on Northwest Biotherapeutics had gone badly.